Home > Press > Nanogate AG exceeds annual forecast and predicts significant growth in 2008
Abstract:
Sales and EBT growing at almost 33% - forecast exceeded - core business achieves margin of approximately 22% - international sales more than double - 2008 annual forecast: sales growth of EUR 12.5m to 14.5m - EBT of EUR 0.7m to 1m due to planned high investment activity
Nanogate AG (ISIN DE000A0JKHC9) has exceeded its annual forecast for the completed 2007 financial year. Nanogate has moved forward more quickly than originally expected in the opening up of international markets and the development of new technology platforms.
Group sales increased in the 2007 financial year by 32.8% to EUR 10.4m, while overall performance grew by 39.9% to around EUR 12.4m. The company profited here from high growth in the Multifunctional Surfaces core business, which increased by around 40%. International sales increased by 136% from EUR 1.1m to around EUR 2.6m. Earnings before taxes (EBT, according to IFRS) climbed in the reporting period by 32.8% to EUR 1.5m, meaning this growth company exceeded its forecast by around 50%. In the Multifunctional Surfaces core business the segment result doubled; the earnings margin of 21.8% confirmed the high profitability and strong performance.
The adjusted earnings per share improved by 9.7% to EUR 0.68. Cash flow from operating activities reflected the positive operational development and increased by 32% to around EUR 1.6m. The majority of all investments were thus financed directly from the operating result. The high equity ratio of 84% and available cash funds of around EUR 12.4m thus remained almost unchanged.
Important milestones reached in 2007
During the reporting period Nanogate expanded its good market position both operationally and strategically. The milestones included market entry in the US, the first cooperation agreement on the groundbreaking optics technology and the initiated expansion of the equity holding in the subsidiary Holmenkol. Furthermore, pioneering technology platforms, including Dotfarm® optics und NanoPlating™, were further developed for high margin and high volume applications. With around 30 additional solutions operationally implemented for customers, the number of applications rose overall to more than 150. For example, in the exhaust gas recirculation valve segment two new models were put into mass production and already more than 300.000 diesel vehicles have been fitted with them.
Looking ahead in 2008: significant growth planned
Nanogate started the 2008 financial year well. The consistently high demand confirms the strategic direction of the Group. Moreover, the US partner began the marketing of jointly refined premium products in the bathroom segment. The new NanoGuard® product line of innovative surface sealing for buildings has been marketed since the start of the year - cooperation with Dow Corning in the US is thus running according to plan. The opening up of new markets in the optics segment is making good progress: in April Nanogate concluded a second cooperation agreement in the LCD segment and thus managed to enter the Japanese market. Initial conversations were begun in the LED segment regarding commercial marketing.
In the course of this year, the company wants to further increase its market permeation. Further applications are intended to win additional customers in new regions. The focus is in particular on markets with a long-term sales potential of at least EUR 10m and good chances for growth. The investment programme in the Advanced Applications segment in particular is thus being strongly expanded in order to exploit the medium- and long-term opportunities even better. In the Multifunctional Surfaces core business, attractive results are expected. In total, Nanogate is reckoning with a sales increase of EUR 12.5m to 14.5m. Despite the planned substantial deployment of funds and investments for new technologies and the opening of new markets, the earnings before taxes (EBT) is expected to be EUR 0.7m to 1m.
Ralf Zastrau, Chairman of the Management Board of Nanogate AG: "Nanogate has created key conditions for sustained growth and exceeded the operating targets. Now we will lead the company systematically into a new corporate phase and realise sales potential with the new technology platforms in the high eight figure range and attractive margins in the medium term."
####
About Nanogate AG
The Nanogate AG is an internationally leading enabler in the growth market of nanotechnology. We enhance our customers´ and partners´ products, hence providing them with extra added value and a competitive edge. We open the gateway to nanotechnology for the most varied of industrial sectors.
Taking Nanogate Technologie® as a basis, we create new functions by programming materials. From the development and production of innovative nano composites and nano formulations through to comprehensive product and process integration, we offer competence as a partner in innovation and implementation. Take advantage of our added value potential!
For more information, please click here
Contacts:
MPW FINANCE
Public & Investor Relations GmbH
Klaus Reuning
Tel. +49 (0)69/959290-0
Fax +49 (0)69/ 959290-29
Copyright © Nanogate AG
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Possible Futures
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||